Phase
Condition
Multiple Sclerosis
Amyotrophic Lateral Sclerosis (Als)
Metabolic Disorders
Treatment
Normal Saline as Placebo
nexiguran ziclumeran
Clinical Study ID
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosis of ATTRv-PN
Karnofsky Performance Status (KPS) ≥ 60
Exclusion
Exclusion Criteria:
Other causes of amyloidosis (amyloidosis caused by non-TTR protein)
Other known causes of sensorimotor or autonomic neuropathy
Diabetes mellitus
New York Heart Association Class III or IV heart failure
Liver failure
Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisenseoligonucleotides (ASOs))
Estimated Glomerular Filtration Rate < 30 mL/min/1.73 m2
Unable or unwilling to take vitamin A supplementation for the duration of the study
Study Design
Study Description
Connect with a study center
Westmead Hospital
Westmead,
AustraliaActive - Recruiting
PSEG Centro de Pesquisa Clinica S.A.
Sao Paulo,
BrazilActive - Recruiting
New Zealand Clinical Research
Auckland,
New ZealandActive - Recruiting
National Taiwan University Hospital
Taipei,
TaiwanActive - Recruiting
Taipei Veterans General Hospital
Taipei,
TaiwanActive - Recruiting
Chang Gung Medical Foundation - Linkou Branch
Taoyuan,
TaiwanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.